The latest biotech news

News and Trends 25 May 2017

Resilient Tumor Cells Drive Breast Cancer Relapse in Mice

Tumor cells that survive chemotherapy and drive breast cancer relapse may provide drug targets for potential treatments to reduce the recurrence. In mice, some breast tumor cells can survive chemotherapy and drive the recurrence of tumor, found a team of researchers from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany and in Monterotondo, Italy; […]

May 25, 2017 - 3 minutesmins - By External Contributor

News and Trends 24 May 2017

UK biotech is catching up to the US, but will it run out of gas?

The UK is far ahead of its European biotech rivals according to a new report, but will it fulfill its promise of becoming a global hub? According to analysis by the BioIndustry Association, the UK is catching up to global biotech leaders San Francisco and Boston, both in finance and R&D. British biotechs banked £1.13B last year, and […]

May 24, 2017 - 5 minutesmins - By Evelyn Warner

News and Trends 24 May 2017

French Biotech Enters New Agreement to Advance its IBD Immunotherapy

OSE Immunotherapeutics has teamed up with Selexis in a new license agreement to support the development of its IL-7 antagonist for the treatment of IBD. In the end of last year, French OSE Immunotherapeutics joined forces with Servier to develop and commercialize its interleukin-7 antagonist (Effi-7) in a deal that could earn the biotech up […]

May 24, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 24 May 2017

Curious about Who is Living in Your Gut? This Kit Can Tell You

Personalized and democratized medicine is coming to the microbiome via a new initiative, FeelGut, from Biopolis. The FeelGut kit lets you explore your gut! FeelGut is a new kit for those of us who want to explore their microbiota. It’s developed by Biopolis, a Spanish biotech committed to empowering people through improved understanding and control of […]

May 24, 2017 - 3 minutesmins - By External Contributor

Oryx glioblastoma ParvOryx combination 1

News and Trends 23 May 2017

German Biotech Tops Up its Oncolytic Virus with Immuno-Oncology Drugs

Oryx has reported good clinical data on the combination of its oncolytic virus with immuno-oncology drugs, convincing the biotech to start clinical trials. Based in Munich, Oryx is developing cancer immunotherapies for a number of solid tumors consisting of oncolytic viruses and peptide vaccines. The company just announced positive clinical data for 16 patients treated under compassionate use […]

May 23, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 23 May 2017

Merck to Pay Ablynx €15M for Getting a Second Nanobody ready for the Clinic

Ablynx is receiving its first milestone payment from a deal with Merck for the development of first-in-class treatments for osteoarthritis. Belgium-based Ablynx develops nanobodies, molecules with the same properties as antibodies but with the advantage of being much smaller. This technology has attracted top pharma partners like AbbVie, MSD, Boehringer Ingelheim and Novartis. Now, the third […]

May 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 May 2017

Norwegian Biotech Goes for Combination Therapies in Melanoma

BerGenBio has started a new Phase I/II trial evaluating the addition of its Axl inhibitor to standard of care treatments in advanced melanoma. In March, Norwegian BerGenBio beat a biotech record on the Norwegian stock exchange, raising a massive €43.55M. Now, the company is standing by its promises and just dosed the first patient in a […]

May 22, 2017 - 2 minutesmins - By Melanie De Almeida

argenx llama antibody immuno oncology IPO

News and Trends 22 May 2017

UPDATE: Argenx’s IPO soars to over €100M to prove itself in Phase II

UPDATE (22/05/2017): Argenx has gone above and beyond to secure $115M (€103M) on the NASDAQ. Underwriters claimed all of the shares offered in over allotment, bringing the IPO to 50% more than the initial goal. Rather a lot for a company whose compound has yet to prove itself in Phase II. UPDATE (24/04/2017): Pricing terms have yet to be set, but the […]

May 22, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 May 2017

A Concert Played by Human Neurons on a Petri Dish

Guy Ben-Ary grew his own neurons on a Petri dish and made them perform in a concert last weekend at the Haus der Kulturen der Welt in Berlin. Last weekend I took my bike across Berlin to attend a truly unique event. It was, in fact, my first time going to a concert where one […]

May 20, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Iterum Therapeutics antibiotics series b fundraising

News and Trends 19 May 2017

Irish Biotech developing New Antibiotics attracts €58M in Series B Round

Iterum Therapeutics has raised €58M to fund Phase III and bring a new antibiotic to a market where innovation is lacking. Iterum Therapeutics is a biotech based in Dublin that develops new antibiotics with the aim of combating the superbug crisis. The company has just raised €58M ($65M) in Series B to fund Phase III […]

May 19, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 May 2017

Shining new Light on how to control Cell Circuits

Controlling genes with light is a new therapeutic avenue, and researchers from Finland are exploring how it can be used to tinker with the cell’s biochemical circuitry. Their findings could provide a better understanding of degenerative diseases and yield new cancer treatments. Researchers from the Turku Centre for Biotechnology at the University of Turku and Åbo […]

May 19, 2017 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 19 May 2017

MorphoSys’ First Lanthipeptide Completes Phase I Successfully

UPDATE (19/05/2017): MorphoSys has announced the completion of the Phase I study with MOR107, which has proved safe and showed dose-dependent pharmacokinetics. The drug, an agonist of the angiotensin II receptor type 2 (AT2-R), comes from the Dutch Lanthio Pharma and is the first lanthipeptide in MorphoSys’ pipeline. Originally published 21/02/2017 Lanthio Pharma has initiated a […]

May 19, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Resilient Tumor Cells Drive Breast Cancer Relapse in Mice

UK biotech is catching up to the US, but will it run out of gas?

French Biotech Enters New Agreement to Advance its IBD Immunotherapy

Curious about Who is Living in Your Gut? This Kit Can Tell You

German Biotech Tops Up its Oncolytic Virus with Immuno-Oncology Drugs

Merck to Pay Ablynx €15M for Getting a Second Nanobody ready for the Clinic

Norwegian Biotech Goes for Combination Therapies in Melanoma

UPDATE: Argenx’s IPO soars to over €100M to prove itself in Phase II

A Concert Played by Human Neurons on a Petri Dish

Irish Biotech developing New Antibiotics attracts €58M in Series B Round

Shining new Light on how to control Cell Circuits

MorphoSys’ First Lanthipeptide Completes Phase I Successfully

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!